Return to Alert Listing ...

 Lymphoma Treatment News

The potential for heart damage from doxorubicin, one of the drugs included
in the CHOP chemotherapy regime for non-Hodgkin's lymphoma and the ABVD plan for Hodgkin's lymphoma, has long been one of the challenges associated
with lymphoma treatment. Recently, researchers in Japan have found that patients
who were given valsartan (an angiotensin II receptor inhibitor -- a drug that 
affects a particular aspect of heart chemistry) along with CHOP chemotherapy 
for NHL did not experience most of the short-term heart changes that CHOP 
patients usually experience. It is not clear whether use of valsartan will 
also improve the long-term heart health of CHOP patients. 

          While this study shows very promising results from the use of valsartan, 
medical practice is not based on the results of a single study. More studies 
replicating these results, and more knowledge on the long-term results of 
valsartan use along with doxorubin, are needed.

Nakamae, H.; Tsumura, K., Terada, Y.; Nakane, T.; Nkamae, M.; Ohta, K.; 
Yamane, T.; and Hino, M. Notable effects of angiotensin II receptor blocker, 
valsartan, on acute cardiotoxic changes after standard chemotherapy with 
cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104 (11), 
Dec. 1, 2005, 2492-8.

Lymphoma Foundation of America
Main Office
1100 N. Main Street
Ann Arbor, MI 48104
Tel: (734) 222-1100 | Fax: (734) 222-1100

Patient Hotline: 1-800-385-1060

This site does not contain any drug company advertisements or industry promotions.